MedTrace Logo

Genomic and Phenotypic Determinants of Resistance to Immunotherapies in Multiple Myeloma

NCT03848676 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2024-12-11

No results posted yet for this study

Summary

A total of 40 Multiple Myeloma (MM) patients at clinical relapse who progressed during Proteasome Inhibitors (PIs) or Immunomodulating Drugs (IMiDs)-based therapies and who are assigned to antiCD38-based salvage treatments, will be enrolled. We will collect bone marrow (BM) and peripheral blood (PB) samples from patients at specific timepoints:

* baseline (BM, PB and buccal swab)
* every 3 month (PB)
* achievement of response (≥ Very Good Partial Response (VGPR)) (BM and PB)
* relapse or refractory status to antiCD38-based treatments (BM and PB) Samples will be processed and stored in the "Hematological Laboratory" located in the University of Turin (Italy) for various proposed analyses: at specific time-points CD138+ (Plasma Cells-PCs) and marker CD138/19+ (B cells) will be immunomagnetically enriched from the BM mononuclear cells and frozen as viable cells in dimethyl sulfoxide (DMSO); PB mononuclear cells (PBMCs) will be isolated from whole blood by density-gradient centrifugation, and frozen as above; plasma fraction from PB and BM will be obtained by centrifugation and stored frozen; a buccal swab will be obtained at the time of enrollment as a source of control germline DNA and stored frozen.

Conditions

Interventions

DIAGNOSTIC_TEST

Evaluation of patients resistance to immunotherapies in Multiple Myeloma

There are only collections of the samples.

Sponsors & Collaborators

  • University of Turin, Italy

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-01
Primary Completion
2024-07-01
Completion
2024-12-10

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03848676 on ClinicalTrials.gov